Chronic total occlusion percutaneous coronary interventions: identifying patients at risk of complications.

Chronic total occlusion PCI Complications high risk PCI major Adverse Cardiovascular Events percutaneous Coronary Intervention

Journal

Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 30 4 2020
medline: 7 10 2020
entrez: 30 4 2020
Statut: ppublish

Résumé

Angina refractory to medical therapy and providing complete revascularization (after acute coronary syndrome or in patients with ischemic cardiomyopathy) are common indications for chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Unfortunately, CTO PCI is associated with higher rates of complications when compared with non-CTO PCI. In this article, we review available studies on risk prediction in CTO PCI and outline strategies to avoid complications. Identifying patients at increased risk of periprocedural major adverse cardiovascular events (MACE) is of great importance. It enhances the conversations about the risk and benefits of CTO PCI and it allows for shared decision making when deciding to undergo or forego such procedures.

Identifiants

pubmed: 32345070
doi: 10.1080/14779072.2020.1760091
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

269-275

Auteurs

Saroj Neupane (S)

Department of Internal Medicine, WakeMed Hospital , Raleigh, NC, USA.

Ankur Gupta (A)

Division of Cardiology, Henry Ford Hospital/Wayne State University , Detroit, MI, USA.

Mir Basir (M)

Division of Cardiology, Henry Ford Hospital/Wayne State University , Detroit, MI, USA.

Khaldoon Alaswad (K)

Division of Cardiology, Henry Ford Hospital/Wayne State University , Detroit, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH